Cryolife (CRY) 11.30 $CRY
CryoLife declares $0.03 dividend
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:46AM CST
CRY: 11.30 (-0.10)
CryoLife Announces Quarterly Cash Dividend for the First Quarter 2015
PR Newswire - Fri Feb 13, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2015 of $0.03 per share of common stock outstanding. The quarterly cash dividend of $0.03 per share will be paid on March 20, 2015 to all common stockholders of record as of March 13, 2015. The ex-dividend date for the quarterly dividend is March 11, 2015.
CRY: 11.30 (-0.10)
U.S. & European Heart Valve Market Overview 2014
M2 - Tue Feb 10, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/l83sqr/u_s_and_european) has announced the addition of the "U.S. & European Heart Valve Market" report to their offering. The surgical heart valve market consists of both mechanical and tissue heart valves. Tissue heart valves consist of stented, stentless and sutureless tissue heart valves. Stented heart valves have long been the industry standard; however, stentless and sutureless valves are expected to show a strong presence over the forecast period. A sutureless valve differs from traditional tissue heart valves in that it is self-anchoring and thus does not need to be sutured in place. Thus, sutureless heart valves require a shorter procedure time than traditional tissue heart valves, and are able to be delivered minimally invasively. The sutureless heart valve market is expected to increase its share approximately threefold. The market has a competitive landscape with each competitor having quality and clinically supported products available. A critical note for the surgical heart valve market is that the growth of the transcatheter heart valve implantation device market has not had a substantial impact on the demand for surgical heart valves, indicating that the various valve technologies treat different patient populations. Key Topics Covered: 1. Research Methodology 2. Heart Valve Device And Procedure Overview 3. U.S. Tissue Heart Valve Market 4. European Tissue Heart Valve Market 5. U.S. Mechanical Heart Valve Market 6. European Mechanical Heart Valve Market 7. U.S. Annuloplasty Repair Device Market 8. European Annuloplasty Repair Device Market 9. U.S. Transcatheter Mitral Valve Repair Device Market 10. European Transcatheter Mitral Valve Repair Market 11. U.S. Transcatheter Heart Valve Implantation Device Market 12. European Transcatheter Heart Valve Implantation Device Market Companies Mentioned - Cardiac Dimensions - Cardiosolutions - CryoLife - Direct Flow Medical - Edwards LifeSciences - Endovalve Inc - JenaValve - JenaValve Technology - Medtronic - MiCardia - Sandra Medical - Sorin - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/l8...d_european
MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), EW: 134.23 (+1.89), CRY: 11.30 (-0.10)
CryoLife Announces Release Date and Teleconference Call Details for 2014 Fourth Quarter and Year End Financial Results
PR Newswire - Thu Feb 05, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 fourth quarter and year end financial results will be released on Tuesday, February 17, 2015. On that day, the Company will hold a teleconference call and live webcast at 8:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, president and chief executive officer of CryoLife, Inc.
CRY: 11.30 (-0.10)
Global Organ and Tissue Transplantation Market
PR Newswire - Thu Jan 29, 7:27AM CST
This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments - Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs). The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine), Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), and Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -
EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
CryoLife Founder and Executive Chairman Steven Anderson to Receive 2015 Georgia Bio Industry Growth Award
PR Newswire - Wed Jan 21, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Founder and Executive Chairman, Steven G. Anderson, will receive a 2015 Georgia Bio Industry Growth Award. Mr. Anderson is being honored for his dedication to the implantable medical device industry in the state of Georgia.
CRY: 11.30 (-0.10)
CryoLife, Inc.: A Premium Healthcare Stock
Danny Katz - at Seeking Alpha - Fri Jan 02, 12:43AM CST
CRY: 11.30 (-0.10)
CryoLife Inc. (CRY) in Focus: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 7:37AM CST
CryoLife Inc. (CRY) was a big mover last session, as the company saw its shares rise more than 7% on the day.
INGN: 33.53 (+2.32), CRY: 11.30 (-0.10)
NYSE stocks posting largest percentage increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
LEN: 49.98 (-0.28), HTZ: 23.00 (-0.24), BBG: 12.56 (+0.55), CHK: 21.08 (+0.58), KN: 18.59 (-3.05), LEN.B: 40.12 (-0.13), LXFR: 13.60 (-0.02), BCEI: 28.74 (+0.16), CRY: 11.30 (-0.10), GCAP: 8.67 (+0.17), USAC: 19.07 (+0.61)
Upgrade Alert for CryoLife (CRY)
Comtex SmarTrend(R) - Tue Dec 23, 6:59AM CST
CryoLife (NYSE:CRY) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $10.39 on volume of 160,000 shares, above average daily volume of 110,000. CryoLife (NYSE:CRY) has potential upside of 15.5% based on a current price of $10.39 and analysts' consensus price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $10.21 and subsequent support at its 200-day MA of $9.73.
CRY: 11.30 (-0.10)
CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Nov 24, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at The New York Palace Hotel in New York City.
CRY: 11.30 (-0.10)
How To YieldBoost CRY To 17.1% Using Options
StockOptionsChannel.com - Wed Nov 19, 10:48AM CST
Shareholders of CryoLife, Inc. looking to boost their income beyond the stock's 1.3% annualized dividend yield can sell the April 2015 covered call at the $10 strike and collect the premium based on the 60 cents bid, which annualizes to an...
CRY: 11.30 (-0.10)
CryoLife Earnings In Retrospect: Down 7.0% in the Last 20 Days (CRY)
Comtex SmarTrend(R) - Mon Nov 17, 2:24PM CST
20 days ago, on October 28th, 2014, CryoLife (NYSE:CRY) reported its earnings. Analysts, on average, expected earnings of $0.04 per share on sales of $37.7 million. CryoLife actually reported earnings of $0.08 per share on sales of $37.1 million, beating EPS estimates by $0.04 and missing revenue estimates by $0.6 million. Shares of CryoLife have slipped from $10.41 to $9.68, representing a loss of 7.0%, since the company reported earnings 20 days ago.
CRY: 11.30 (-0.10)
CryoLife to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Thu Nov 13, 4:04PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming Canaccord Genuity 2014 Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at the Westin Grand Central Hotel in New York.
CRY: 11.30 (-0.10)
Update: CryoLife Q3 2014 Earnings, Book Profit
Andy Batts - at Seeking Alpha - Mon Nov 10, 1:08AM CST
CRY: 11.30 (-0.10)
CryoLife Q3 Earnings Fall, Revenues Rise Y/Y; Shares Tank - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:00PM CST
CryoLife Inc. (CRY) reported adjusted earnings per share of 8 cents in the third quarter of fiscal 2014, lower than the year-ago earnings of 11 cents.
CYNO: 31.37 (+0.80), FLDM: 37.93 (-0.47), CRY: 11.30 (-0.10), ANGO: 18.78 (+0.18)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 75.26 (+0.33), EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
CryoLife's (CRY) CEO Patrick Mackin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:12PM CDT
CRY: 11.30 (-0.10)
CryoLife revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:29PM CDT
CRY: 11.30 (-0.10)
CryoLife declares $0.03 dividend
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:46AM CST
CRY: 11.30 (-0.10)
CryoLife Announces Quarterly Cash Dividend for the First Quarter 2015
PR Newswire - Fri Feb 13, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2015 of $0.03 per share of common stock outstanding. The quarterly cash dividend of $0.03 per share will be paid on March 20, 2015 to all common stockholders of record as of March 13, 2015. The ex-dividend date for the quarterly dividend is March 11, 2015.
CRY: 11.30 (-0.10)
U.S. & European Heart Valve Market Overview 2014
M2 - Tue Feb 10, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/l83sqr/u_s_and_european) has announced the addition of the "U.S. & European Heart Valve Market" report to their offering. The surgical heart valve market consists of both mechanical and tissue heart valves. Tissue heart valves consist of stented, stentless and sutureless tissue heart valves. Stented heart valves have long been the industry standard; however, stentless and sutureless valves are expected to show a strong presence over the forecast period. A sutureless valve differs from traditional tissue heart valves in that it is self-anchoring and thus does not need to be sutured in place. Thus, sutureless heart valves require a shorter procedure time than traditional tissue heart valves, and are able to be delivered minimally invasively. The sutureless heart valve market is expected to increase its share approximately threefold. The market has a competitive landscape with each competitor having quality and clinically supported products available. A critical note for the surgical heart valve market is that the growth of the transcatheter heart valve implantation device market has not had a substantial impact on the demand for surgical heart valves, indicating that the various valve technologies treat different patient populations. Key Topics Covered: 1. Research Methodology 2. Heart Valve Device And Procedure Overview 3. U.S. Tissue Heart Valve Market 4. European Tissue Heart Valve Market 5. U.S. Mechanical Heart Valve Market 6. European Mechanical Heart Valve Market 7. U.S. Annuloplasty Repair Device Market 8. European Annuloplasty Repair Device Market 9. U.S. Transcatheter Mitral Valve Repair Device Market 10. European Transcatheter Mitral Valve Repair Market 11. U.S. Transcatheter Heart Valve Implantation Device Market 12. European Transcatheter Heart Valve Implantation Device Market Companies Mentioned - Cardiac Dimensions - Cardiosolutions - CryoLife - Direct Flow Medical - Edwards LifeSciences - Endovalve Inc - JenaValve - JenaValve Technology - Medtronic - MiCardia - Sandra Medical - Sorin - St. Jude Medical For more information visit http://www.researchandmarkets.com/research/l8...d_european
MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), EW: 134.23 (+1.89), CRY: 11.30 (-0.10)
CryoLife Announces Release Date and Teleconference Call Details for 2014 Fourth Quarter and Year End Financial Results
PR Newswire - Thu Feb 05, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 fourth quarter and year end financial results will be released on Tuesday, February 17, 2015. On that day, the Company will hold a teleconference call and live webcast at 8:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, president and chief executive officer of CryoLife, Inc.
CRY: 11.30 (-0.10)
Global Organ and Tissue Transplantation Market
PR Newswire - Thu Jan 29, 7:27AM CST
This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments - Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs). The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine), Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), and Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -
EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
CryoLife Founder and Executive Chairman Steven Anderson to Receive 2015 Georgia Bio Industry Growth Award
PR Newswire - Wed Jan 21, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Founder and Executive Chairman, Steven G. Anderson, will receive a 2015 Georgia Bio Industry Growth Award. Mr. Anderson is being honored for his dedication to the implantable medical device industry in the state of Georgia.
CRY: 11.30 (-0.10)
CryoLife, Inc.: A Premium Healthcare Stock
Danny Katz - at Seeking Alpha - Fri Jan 02, 12:43AM CST
CRY: 11.30 (-0.10)
CryoLife Inc. (CRY) in Focus: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 7:37AM CST
CryoLife Inc. (CRY) was a big mover last session, as the company saw its shares rise more than 7% on the day.
INGN: 33.53 (+2.32), CRY: 11.30 (-0.10)
NYSE stocks posting largest percentage increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
LEN: 49.98 (-0.28), HTZ: 23.00 (-0.24), BBG: 12.56 (+0.55), CHK: 21.08 (+0.58), KN: 18.59 (-3.05), LEN.B: 40.12 (-0.13), LXFR: 13.60 (-0.02), BCEI: 28.74 (+0.16), CRY: 11.30 (-0.10), GCAP: 8.67 (+0.17), USAC: 19.07 (+0.61)
Upgrade Alert for CryoLife (CRY)
Comtex SmarTrend(R) - Tue Dec 23, 6:59AM CST
CryoLife (NYSE:CRY) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $10.39 on volume of 160,000 shares, above average daily volume of 110,000. CryoLife (NYSE:CRY) has potential upside of 15.5% based on a current price of $10.39 and analysts' consensus price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $10.21 and subsequent support at its 200-day MA of $9.73.
CRY: 11.30 (-0.10)
CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Mon Nov 24, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at The New York Palace Hotel in New York City.
CRY: 11.30 (-0.10)
How To YieldBoost CRY To 17.1% Using Options
StockOptionsChannel.com - Wed Nov 19, 10:48AM CST
Shareholders of CryoLife, Inc. looking to boost their income beyond the stock's 1.3% annualized dividend yield can sell the April 2015 covered call at the $10 strike and collect the premium based on the 60 cents bid, which annualizes to an...
CRY: 11.30 (-0.10)
CryoLife Earnings In Retrospect: Down 7.0% in the Last 20 Days (CRY)
Comtex SmarTrend(R) - Mon Nov 17, 2:24PM CST
20 days ago, on October 28th, 2014, CryoLife (NYSE:CRY) reported its earnings. Analysts, on average, expected earnings of $0.04 per share on sales of $37.7 million. CryoLife actually reported earnings of $0.08 per share on sales of $37.1 million, beating EPS estimates by $0.04 and missing revenue estimates by $0.6 million. Shares of CryoLife have slipped from $10.41 to $9.68, representing a loss of 7.0%, since the company reported earnings 20 days ago.
CRY: 11.30 (-0.10)
CryoLife to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Thu Nov 13, 4:04PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming Canaccord Genuity 2014 Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at the Westin Grand Central Hotel in New York.
CRY: 11.30 (-0.10)
Update: CryoLife Q3 2014 Earnings, Book Profit
Andy Batts - at Seeking Alpha - Mon Nov 10, 1:08AM CST
CRY: 11.30 (-0.10)
CryoLife Q3 Earnings Fall, Revenues Rise Y/Y; Shares Tank - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:00PM CST
CryoLife Inc. (CRY) reported adjusted earnings per share of 8 cents in the third quarter of fiscal 2014, lower than the year-ago earnings of 11 cents.
CYNO: 31.37 (+0.80), FLDM: 37.93 (-0.47), CRY: 11.30 (-0.10), ANGO: 18.78 (+0.18)
Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 75.26 (+0.33), EXAC: 22.33 (-0.28), CRY: 11.30 (-0.10)
CryoLife's (CRY) CEO Patrick Mackin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:12PM CDT
CRY: 11.30 (-0.10)
CryoLife revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 12:29PM CDT
CRY: 11.30 (-0.10)
